Following a request of the European Commission, the European Food Safety Authority (EFSA) reviewed the scientific arguments raised by Testbiotech against the Commission Implementing Decision (EU) 2018/2046 authorising the placing on the market of products containing, consisting of, or produced from maize MON 87427 × MON 89034 × 1507 × MON 88017 × 59122 and its subcombinations (application EFSA‐GMO‐BE‐2013‐118). Testbiotech argued that the risk assessment of maize MON 87427 × MON 89034 × 1507 × MON 88017 × 59122 and its subcombinations performed by the EFSA GMO Panel is inadequate as regards molecular characterisation, comparative analyses, toxicological and allergenicity assessment, and environmental assessment. EFSA analysed each of the scientific arguments put forward in the technical background of Testbiotech's complaint on maize MON 87427 × MON 89034 × 1507 × MON 88017 × 59122 and its subcombinations and concludes that none reveals new information that would invalidate the previous risk assessment conclusions and risk management recommendations made by the EFSA GMO Panel. Therefore, EFSA considers that the previous EFSA GMO Panel risk assessment conclusions and risk management recommendations on maize MON 87427 × MON 89034 × 1507 × MON 88017 × 59122 and its subcombinations remain valid and applicable.